Halozyme Therapeutics, Inc. (HALO) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Halozyme Therapeutics reported revenue of $1.40B, up 37.6% from $1.02B the year before. Net income was $316.9M (a 22.7% net margin), or $2.56 per diluted share. Gross margin was 83.6% and operating margin was 33.6%. Operating activities generated $651.6M of cash, leaving $644.6M of free cash flow. At fiscal year end, Halozyme Therapeutics held $2.53B in total assets against $2.48B in total liabilities, including $133.8M of cash and equivalents.
Open the full interactive Halozyme Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Halozyme Therapeutics Key Stats
| Share Price | $109.62 |
|---|---|
| Market Cap | $13.29B |
| P/E Ratio | 42.8 |
| Revenue YoY Growth | +37.5% |
| 52-Week Range | $61.63 – $115.22 |
| Shares Outstanding | 117.3 million (basic, 2026 Q2) |
Halozyme Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $267.6M | $443.3M | $660.1M | $829.3M | $1.02B | $1.40B |
| Cost of Goods Sold | $43.4M | $81.4M | $139.3M | $192.4M | $159.4M | $228.8M |
| Gross Profit | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.17B |
| Operating Income | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $469.0M |
| Pre-Tax Income | $129.3M | $248.5M | $248.9M | $348.3M | $557.1M | $466.9M |
| Income Tax | $217,000 | -$154.2M | $46.8M | $66.7M | $113.0M | $150.0M |
| Net Income | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| Diluted EPS | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
Halozyme Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $354.3M | $451.8M | $376.7M | $481.0M |
| Net Income | $175.2M | -$141.6M | $150.0M | $229.9M |
| Diluted EPS | $1.43 | -$1.14 | $1.22 | $1.90 |
Halozyme Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $147.7M | $118.7M | $234.2M | $118.4M | $115.8M | $133.8M |
| Current Assets | $554.8M | $926.3M | $739.0M | $746.4M | $1.09B | $825.2M |
| Total Assets | $579.9M | $1.10B | $1.84B | $1.73B | $2.06B | $2.53B |
| Current Liabilities | $421.4M | $117.1M | $130.8M | $112.5M | $139.1M | $177.1M |
| Total Long-Term Debt | $397.2M | $876.7M | $1.51B | $1.50B | $1.51B | $2.14B |
| Total Liabilities | $428.9M | $907.5M | $1.67B | $1.65B | $1.70B | $2.48B |
| Shareholders' Equity | $151.0M | $197.0M | $169.8M | $83.8M | $363.8M | $48.8M |
Halozyme Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M | $651.6M |
| Cash From Investing | $78.4M | -$406.3M | -$487.0M | -$96.9M | -$262.7M | -$545.8M |
| Cash From Financing | -$106.3M | $77.9M | $362.4M | -$408.0M | -$218.9M | -$85.2M |
| Free Cash Flow | $53.0M | $298.0M | $235.3M | $373.3M | $468.4M | $644.6M |
Figures from Halozyme Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Halozyme Therapeutics financials page for every line item.
Halozyme Therapeutics Company Profile
| Ticker | HALO |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001159036 |
Frequently Asked Questions
What was Halozyme Therapeutics' revenue in fiscal 2025?
Halozyme Therapeutics (HALO) reported revenue of $1.40B for fiscal 2025.
What is Halozyme Therapeutics' annual revenue history?
Halozyme Therapeutics' annual revenue by fiscal year: 2020: $267.6M; 2021: $443.3M; 2022: $660.1M; 2023: $829.3M; 2024: $1.02B; 2025: $1.40B.
What was Halozyme Therapeutics' net income in fiscal 2025?
Halozyme Therapeutics reported net income of $316.9M for fiscal 2025.
What was Halozyme Therapeutics' earnings per share (EPS) in fiscal 2025?
Halozyme Therapeutics' diluted EPS was $2.56 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Halozyme Therapeutics generate in fiscal 2025?
Halozyme Therapeutics generated $644.6M of free cash flow in fiscal 2025.
What was Halozyme Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Halozyme Therapeutics reported revenue of $481.0M.
How much debt does Halozyme Therapeutics have?
Halozyme Therapeutics reported $2.14B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Halozyme Therapeutics are outstanding?
Halozyme Therapeutics reported a weighted average of 117.3 million basic shares outstanding in 2026 Q2.
What is Halozyme Therapeutics' market cap?
Based on its latest closing price, Halozyme Therapeutics (HALO) has a market capitalization of about $13.29B.
When does Halozyme Therapeutics' fiscal year end?
Halozyme Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Halozyme Therapeutics headquartered?
Halozyme Therapeutics lists its business address in San Diego, California in its SEC filings.
Halozyme Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →